好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Understanding Frequency and Characteristics of Prolonged Seizures Using Seizure Diary Data
Epilepsy/Clinical Neurophysiology (EEG)
P9 - Poster Session 9 (5:00 PM-6:00 PM)
11-007
To evaluate the prevalence of prolonged seizures (PS) and associated patient-/seizure-level characteristics in a seizure diary database.
There is a lack of real-world evidence on prevalence and clinical risk factors of PS. PS can negatively impact quality of life, increase risk of injury, and progress to seizure epilepticus (SE). 
Seizures recorded by patients with ≥4 seizures of >0–<60 min duration in SeizureTracker (1/1/2015-12/31/2024), with a ≥30-day gap between first and last seizure, were identified. Seizure-level PS cohort was defined per the 2024 expert consensus panel definition as any convulsive seizure ≥2–<5 min, absence seizure ≥2–<10 min, or focal seizure ≥5–<10 min. SE cohort was any convulsive seizure ≥5 min or any focal/absence seizure ≥10 min. Patient-level cohorts were SE (patients with ≥4 SE seizures), PS (with <4 SE and ≥4 PS), and non-PS. 

Of 734,187 seizures, 5.7%, 10.9%, and 83.4% were SE, PS, and non-PS, respectively. At the seizure-level, most PS were tonic clonic (53.9%). Of 4137 patients (49.5% male, 57.7% aged ≤18 years), 25.0%, 22.3%, and 52.7% constituted the SE, PS, and non-PS cohorts, respectively. More pediatric (65.3%) than adult (34.7%) patients had PS. The frequency of tonic clonic seizures was higher for PS (79.6%) than for SE (67.5%) or non-PS (35.2%) patient cohorts. Aura was more commonly reported in the SE (36.9%) versus other cohorts (27.1% PS, 29.1% non-PS). Irregular sleep, emotional stress, medication changes, and sickness were more common in the SE and PS cohorts than the non-PS cohort. While rescue medication (RM) is not indicated for PS/SE, use of any RM was highest among SE (55.9%) and PS (42.0%) cohorts (28.1% for non-PS).
This real-world data describes the prevalence of PS using patient-reported seizure diary data and may help to support recognition of patients at risk of PS or SE.
Authors/Disclosures
Jaya S. Khushalani, MD, PhD
PRESENTER 		Dr. Khushalani has received personal compensation for serving as an employee of UCB. Dr. Khushalani has or had stock in UCB.
Robert E. Moss Mr. Moss has stock in Seizure Tracker LLC. Mr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as a partial owner of Seizure Tracker LLC with Neuropace. Mr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as a partial owner of Seizure Tracker LLC with Epitel. Mr. Moss has received personal compensation in the range of $10,000-$49,999 for serving as a partial owner of Seizure Tracker LLC with TSC Alliance. Mr. Moss has received personal compensation in the range of $50,000-$99,999 for serving as a partial owner of Seizure Tracker LLC with UCB.
Sharon Chiang, MD, PhD (UCSF) Dr. Chiang has stock in EpilepsyAI. Dr. Chiang has received research support from UCSF Clinical and Translational Science Institute UL1 TR001872. The institution of Dr. Chiang has received research support from NIH R25 NS070680 .
Rebecca Burns, PhD, PharmD Dr. Burns has received personal compensation for serving as an employee of UCB. Dr. Burns has stock in UCB.
Sheryl R. Haut, MD (Albert Einstein College of Medicine) Dr. Haut has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ventus. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbieVe. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Iqvia.